



# SUVEN Life Sciences

**Communication to investors**

**Mar 2017**

13-May-17

*2016-17 Q4 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 4 – Mar 2017



- Growth in income 53.66%
- Growth in PAT 65.09%
- Growth in EBIDTA 27.15%
- Growth in Pre-R&D EBIDTA 24.46%
- Increase in R&D costs 17.59%
- R&D cost on revenue 10.39%

# FINANCIAL QUICK VIEW

## Year ending – Mar 2017



# MAJOR PROFITABILITY RATIOS







	Q4 Mar 17	FY Mar 17
PAT to Income	21.65%	21.83%
EBIDTA to Income	28.69%	32.96%
Cash Flow to Income	25.53%	25.62%
Pre-R&D EBITDA to Income	39.09%	44.45%



# Q4 to Q3 COMPARISON


Current quarter to previous quarter





# INCOME COMPARISON

Year on year




13-May-17

2016-17 Q4 results



# PROFIT COMPARISON

Year on year



13-May-17


2016-17 Q4 results





# EBIDTA COMPARISON

Year on year




13-May-17

2016-17 Q4 results



# R & D – EXPENDITURE

Year on year




13-May-17

2016-17 Q4 results



# PRE-R&D EBIDTA

Year on year




13-May-17

2016-17 Q4 results



# PRE-R&D CASHFLOW

Year on year



13-May-17

2016-17 Q4 results



# Financial Snapshot

All figures are in INR Million, other than ratios and EPS

	2016-17	2015-16	Growth %	2016-17	2015-16	Growth %
	Standalone			Consolidated		
Income	5,655.70	5,195.75	8.85%	5,655.70	5,195.75	8.85%
Pre-R&D EBITDA	2,513.77	2,113.59	18.93%	2,493.12	2,113.09	17.98%
Pre-R&D EBITDA Margin	44.45%	40.68%		44.08%	40.67%	
EBITDA	1,864.36	1,491.85	24.97%	1,501.67	1,209.58	24.15%
EBITDA Margin	32.96%	28.71%		26.55%	23.28%	
EBIT	1,650.23	1,316.88	25.31%	1,287.54	1,034.60	24.45%
EBIT Margin	29.18%	25.35%		22.77%	19.91%	
Financing costs	56.66	58.72		56.83	58.76	
Taxes	358.83	257.36		358.83	257.36	
Net Profit after tax	1,234.74	1,000.80	23.38%	871.87	718.49	21.35%
NP Margin	21.83%	19.26%		15.42%	13.83%	
EPS (basic & diluted not annualised)	9.70	7.86		6.85	5.64	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28	127.28	
Depreciation	214.13	174.97		214.13	174.97	
R&D expenses	649.41	621.74	4.45%	991.45	903.52	9.73%

On consolidation of the accounts of Suven, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 872 Mn and expenditure on R&D increased to INR 991 Mn..

13-May-17

2016-17 Q4 results



# News Release

- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in 76 investigator sites in USA and so far enrolled 219 patients in the study.
- During the period Suven secures 1 product patent in New Zealand.
- Suven presented in ICICI Securities Annual Investor Conference 2017 in February 2017.